Hepatitis D virus and liver transplantation: Indications and outcomes

Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV i...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of hepatology Vol. 13; no. 3; pp. 291 - 299
Main Authors Muhammad, Haris, Tehreem, Aniqa, Hammami, Muhammad Baraa, Ting, Peng-Sheng, Idilman, Ramzan, Gurakar, Ahmet
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 27.03.2021
Subjects
Minireviews
Liver transplant
Hepatocellular carcinoma
Hepatitis B immunoglobins
Hepatitis delta virus
Online AccessGet full text

Cover

More Information
Summary:Hepatitis D virus (HDV) is a dependent virus that relies on hepatitis B virus for its replication and transmission. Chronic hepatitis D is a severe form of viral hepatitis that can result in end stage liver disease. Currently, pegylated interferon alpha is the only approved therapy for chronic HDV infection and is associated with significant side effects. Liver transplantation (LT) is the only treatment option for patients with end-stage liver disease, hepatocellular carcinoma, or fulminant hepatitis due to coinfection with HDV. As LT for HDV and hepatitis B virus coinfection is uncommon in the United States, most data on the long-term impact of LT on HDV are from international centers. In this review, we discuss the indications and results of LT with treatment options in HDV patients.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Author contributions: Muhammad H, Tehreem A and Hammami MB participated in paper design, literature review and writing of the manuscript; Ting PS and Idilman R contributed to critical review and revisions of the manuscript; Gurakar A contributed in paper design, literature review, critical review and revisions of the manuscript; all authors have read and approved the final manuscript.
Corresponding author: Ahmet Gurakar, MD, Associate Professor, Director, Doctor, Division of Gastroenterology and Hepatology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross Research Building, Suite 918, Baltimore, MA 21205, United States. aguraka1@jhmi.edu
ISSN:1948-5182
1948-5182
DOI:10.4254/wjh.v13.i3.291